Literature DB >> 9427378

Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats.

F Block1, A Tondar, W Schmidt, M Schwarz.   

Abstract

In this study the effect of post-treatment with rolipram, an inhibitor of cAMP phosphodiesterase, on neuronal damage following global ischemia was evaluated. Global cerebral ischemia was induced in male Wistar rats by four-vessel occlusion for 20 minutes. Rolipram was administered 6 hours after onset of ischemia and thereafter the following 7 days daily once at a dose of 0.3 or 3.0 mg/kg intraperitoneally. Four weeks after ischemia the amount of intact neurons in the hippocampus and in the striatum was assessed following perfusion fixation. The ischemia-induced neuronal damage in the CA1 sector of the hippocampus and in the striatum was reduced by rolipram at either dose. The present results show that treatment with rolipram reduces ischemic neuronal damage at a therapeutic window of 6 hours.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427378     DOI: 10.1097/00001756-199712010-00033

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  15 in total

Review 1.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.

Authors:  C M Atkins; Y Kang; C Furones; J S Truettner; O F Alonso; W D Dietrich
Journal:  J Neurosci Res       Date:  2012-04-26       Impact factor: 4.164

3.  Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor.

Authors:  T Mamiya; Y Noda; X Ren; M Hamdy; S Furukawa; T Kameyama; K Yamada; T Nabeshima
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

4.  Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats.

Authors:  Ling-Xia Li; Yu-Fang Cheng; Huan-Bing Lin; Chuang Wang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Metab Brain Dis       Date:  2011-02-17       Impact factor: 3.584

5.  Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.

Authors:  Akira Nagakura; Makiko Niimura; Satoshi Takeo
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

6.  A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway.

Authors:  Thong C Ma; Aline Campana; Philipp S Lange; Hsin-Hwa Lee; Kasturi Banerjee; J Barney Bryson; Lata Mahishi; Shabnam Alam; Roman J Giger; Stephen Barnes; Sidney M Morris; Dianna E Willis; Jeffrey L Twiss; Marie T Filbin; Rajiv R Ratan
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

7.  Modulation of the cAMP signaling pathway after traumatic brain injury.

Authors:  Coleen M Atkins; Anthony A Oliva; Ofelia F Alonso; Damien D Pearse; Helen M Bramlett; W Dalton Dietrich
Journal:  Exp Neurol       Date:  2007-08-29       Impact factor: 5.330

8.  Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice.

Authors:  Coleen M Atkins; Maria L Cepero; Yuan Kang; Daniel J Liebl; W Dalton Dietrich
Journal:  Neurosci Lett       Date:  2012-10-26       Impact factor: 3.046

9.  Phosphodiesterase 4 and 7 inhibitors produce protective effects against high glucose-induced neurotoxicity in PC12 cells via modulation of the oxidative stress, apoptosis and inflammation pathways.

Authors:  Nazanin Namazi Sarvestani; Saeedeh Saberi Firouzi; Reza Falak; Mohammad Yahya Karimi; Mohammad Davoodzadeh Gholami; Akram Rangbar; Asieh Hosseini
Journal:  Metab Brain Dis       Date:  2018-04-30       Impact factor: 3.584

10.  The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

Authors:  Sandra Marie Schaal; Maneesh Sen Garg; Mousumi Ghosh; Lilie Lovera; Michael Lopez; Monal Patel; Jack Louro; Samik Patel; Luis Tuesta; Wai-Man Chan; Damien Daniel Pearse
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.